Glaxosmi. Pharma

{
  "main_header": {
    "sid": 793005,
    "name": "Glaxosmi. Pharma",
    "stock_name": "Glaxosmi. Pharma",
    "full_name": "Glaxosmithkline Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/glaxosmi-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,423.65",
    "chg": -2.75,
    "chgp": "-0.11%",
    "dir": -1,
    "prev_price": "2,426.40",
    "mcapval": "41,675.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 500660,
    "symbol": "GLAXO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE159A01016",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "93.83 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glaxosmi-pharma-793005-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3812595",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/Glaxosmithkline_mojoScore_3812595.png",
        "date": "2026-01-31 10:10:05",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 31 January 2026, providing investors with the latest insights into its performance and valuation."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd Hits Intraday High with 5.01% Surge",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-ltd-hits-intraday-high-with-501-surge-3800459",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/Glaxosmithkline_priceRelatedfactors_3800459.png",
        "date": "2026-01-22 14:32:26",
        "description": "Glaxosmithkline Pharmaceuticals Ltd demonstrated robust intraday performance on 22 Jan 2026, surging to an intraday high of Rs 2,391.35, marking a 5.16% increase. The stock outperformed its sector and the broader market, reflecting strong trading momentum amid a mixed market backdrop."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3795953",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/Glaxosmithkline_mojoScore_3795953.png",
        "date": "2026-01-20 10:10:04",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3786884",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/Glaxosmithkline_mojoScore_3786884.png",
        "date": "2026-01-09 10:10:25",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025, reflecting a shift in the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 09 January 2026, providing investors with the latest insights into its performance and valuation."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmithkline-pharmaceuticals-ltd-is-rated-sell-3772297",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/Glaxosmithkline_mojoScore_3772297.png",
        "date": "2025-12-28 10:10:03",
        "description": "Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Why is Glaxosmithkline Pharmaceuticals Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-glaxosmithkline-pharmaceuticals-ltd-fallingrising-3771697",
        "imagepath": "",
        "date": "2025-12-27 00:40:20",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Context</strong></p>\n<p>Glaxosmithkline Pharmaceuticals has underperformed in the immediate term, with a one-week return of -2.94% compared to the Sensex’s modest gain of 0.13%. Over the past month, the stock also lagged the benchmark, declining by 1.13% while the Sensex fell by 0.66%. Despite these short-term setbacks, the stock has delivered a respectable year-to-date return of 9.49%, slightly outperforming the Sensex’s 8.83% gain. Over the last year and three-year periods, the company’s shares have significantly outpaced the benchmark, with returns of 9.73% and 84.99% respectively, underscoring its longer-term resilience.</p>\n<p>However, the recent price action reveals a more cautious investor sentiment. The stock has been on a seven-day losing streak, ..."
      },
      {
        "title": "Glaxosmi. Pharma Sees Revision in Market Assessment Amid Valuation and Technical Challenges",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmi-pharma-downgraded-to-sell-by-marketsmojo-amid-valuation-and-technical-concerns-3761202",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/GlaxosmiPharma_mojoScore_3761202.png",
        "date": "2025-12-17 10:10:20",
        "description": "Glaxosmi. Pharma has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters including valuation, technical outlook, and financial trends. This adjustment highlights evolving investor perspectives on the midcap pharmaceutical company amid a complex sector environment."
      },
      {
        "title": "Glaxosmithkline Pharmaceuticals Faces Bearish Momentum Amid Mixed Technical Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/glaxosmithkline-pharmaceuticals-faces-bearish-momentum-amid-technical-downgrade-3758297",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/Glaxosmithkline_technicaldot_3758297.png",
        "date": "2025-12-15 08:04:02",
        "description": "Glaxosmithkline Pharmaceuticals has experienced a shift in its technical momentum, with recent evaluation adjustments indicating a bearish trend across several key indicators. Despite this, the stock's year-to-date returns continue to outpace the broader Sensex, reflecting a complex interplay between price action and market sentiment within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Glaxosmi. Pharma’s Evaluation Revised Amidst Challenging Market Conditions",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/glaxosmi-pharma-downgraded-to-sell-by-marketsmojo-amid-valuation-concerns-3731005",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/GlaxosmiPharma_mojoScore_3731005.png",
        "date": "2025-11-26 09:46:20",
        "description": "Glaxosmi. Pharma has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment and stock performance within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 5150,
    "sid": "793005",
    "stock_news_url": "https://www.marketsmojo.com/news/glaxosmithkline-pharmaceuticals-793005"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "08-Jan-2026",
      "details": "As per Attachment",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Un-Audited Financial Results For The Third Quarter & Nine Months Ended 31St December 2025.",
      "datetime": "06-Jan-2026",
      "details": "Glaxosmithkline Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 inter alia to consider and approve take on record the Un-audited financial results for the third quarter & nine months ended 31st December 2025.",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30",
      "datetime": "01-Jan-2026",
      "details": "As per attachment",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "09 Feb 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glaxosmithkline Pharmaceuticals Ltd has declared <strong>420%</strong> dividend, ex-date: 30 May 25",
          "dt": "2025-05-30",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Glaxosmithkline Pharmaceuticals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 11 Sep 18",
          "dt": "2018-09-11",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-01-31 10:10:05

Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025, reflecting a reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 31 January 2026, providing investors with the latest insights into its performance and valuation.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd Hits Intraday High with 5.01% Surge

2026-01-22 14:32:26

Glaxosmithkline Pharmaceuticals Ltd demonstrated robust intraday performance on 22 Jan 2026, surging to an intraday high of Rs 2,391.35, marking a 5.16% increase. The stock outperformed its sector and the broader market, reflecting strong trading momentum amid a mixed market backdrop.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-01-20 10:10:04

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2026-01-09 10:10:25

Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025, reflecting a shift in the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 09 January 2026, providing investors with the latest insights into its performance and valuation.

Read full news article

Glaxosmithkline Pharmaceuticals Ltd is Rated Sell

2025-12-28 10:10:03

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Why is Glaxosmithkline Pharmaceuticals Ltd falling/rising?

2025-12-27 00:40:20

Recent Price Performance and Market Context

Glaxosmithkline Pharmaceuticals has underperformed in the immediate term, with a one-week return of -2.94% compared to the Sensex’s modest gain of 0.13%. Over the past month, the stock also lagged the benchmark, declining by 1.13% while the Sensex fell by 0.66%. Despite these short-term setbacks, the stock has delivered a respectable year-to-date return of 9.49%, slightly outperforming the Sensex’s 8.83% gain. Over the last year and three-year periods, the company’s shares have significantly outpaced the benchmark, with returns of 9.73% and 84.99% respectively, underscoring its longer-term resilience.

However, the recent price action reveals a more cautious investor sentiment. The stock has been on a seven-day losing streak, ...

Read full news article

Glaxosmi. Pharma Sees Revision in Market Assessment Amid Valuation and Technical Challenges

2025-12-17 10:10:20

Glaxosmi. Pharma has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters including valuation, technical outlook, and financial trends. This adjustment highlights evolving investor perspectives on the midcap pharmaceutical company amid a complex sector environment.

Read full news article

Glaxosmithkline Pharmaceuticals Faces Bearish Momentum Amid Mixed Technical Signals

2025-12-15 08:04:02

Glaxosmithkline Pharmaceuticals has experienced a shift in its technical momentum, with recent evaluation adjustments indicating a bearish trend across several key indicators. Despite this, the stock's year-to-date returns continue to outpace the broader Sensex, reflecting a complex interplay between price action and market sentiment within the Pharmaceuticals & Biotechnology sector.

Read full news article

Glaxosmi. Pharma’s Evaluation Revised Amidst Challenging Market Conditions

2025-11-26 09:46:20

Glaxosmi. Pharma has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment and stock performance within the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News